[8-K] Karyopharm Therapeutics Inc. Reports Material Event

Rhea-AI Filing Summary

Karyopharm Therapeutics (KPTI) furnished an 8-K announcing its financial results for the quarter ended September 30, 2025, and a previously announced, publicly available conference call to discuss the results and company updates.

The accompanying press release was furnished as Exhibit 99.1 and is incorporated by reference. The company noted that this information, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act.

false000150380200015038022025-11-032025-11-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 3, 2025

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-36167				26-3931704
(State or Other Jurisdiction of Incorporation)		(Commission File Number)				(IRS Employer Identification No.)
85 Wells Avenue, 2nd Floor Newton, Massachusetts				02459
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (617) 658-0600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		KPTI		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 3, 2025, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended September 30, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		Press Release issued by Karyopharm Therapeutics Inc. on November 3, 2025
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				KARYOPHARM THERAPEUTICS INC.
Date: November 3, 2025				By:		/s/ Michael Mano
						Michael Mano
						Senior Vice President, General Counsel and Secretary

FAQ

What did Karyopharm (KPTI) announce in this 8-K?

Karyopharm announced its financial results for the quarter ended September 30, 2025, and a previously announced, publicly available conference call.

Which period do the announced results cover for KPTI?

The results cover the quarter ended September 30, 2025.

How will Karyopharm share more details on the results?

Through a previously announced, publicly available conference call to discuss the results and other company updates.

What is included as Exhibit 99.1 for KPTI?

Exhibit 99.1 is the press release issued on November 3, 2025.

Is the information in this 8-K considered filed or furnished?

It is furnished, not filed, and therefore not subject to Section 18 liabilities of the Exchange Act.

Where is Karyopharm’s stock listed and under what symbol?

Its common stock trades on the Nasdaq Global Select Market under the symbol KPTI.

When was the announcement made?

On November 3, 2025.